WCN26-2361 IMPLEMENTATION AND EVALUATION OF A TEAM APPROACH TO POLYPHARMACY EVALUATION AND REDUCTION (TAPER) AMONG ADULTS WITH CHRONIC KIDNEY DISEASE IN CANADIAN PRIMARY CARE

Read full text Summarise with VIRAT
Authors: Paul Everett Ronksley, Himasara Pathiraja, Dee A. Mangin, Alex Singer, Charlotte Jensen, Leanne Kosowan, Jonathan Gerber, Heidi Cheung, Scott Brimble, Dorothea Nitsch, Kerry McBrien, Tyler S. Williamson
+3 more Allan K. Grill, Neil Drummond, Aminu Bello
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Polypharmacy is a growing public health concern affecting around 40% of older adults. Patients with chronic kidney disease (CKD) are vulnerable to polypharmacy as they require multiple medications to manage CKD progression, its complications and associated comorbidities. Polypharmacy is associated with adverse health outcomes including falls, cognitive impairment, medication non-adherence, and mortality. Despite clinical practice guidelines, potentially inappropriate medication (PIM) use remains common.

Fields of Study & Subjects

Pharmaceutical Practices and Patient Outcomes Pharmacy and Medical Practices Chronic Disease Management Strategies

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104701–104701
Publication date
25 March 2026
Language
EN